NCT06850480View on ClinicalTrials.gov

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

PHASE3RecruitingINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

April 30, 2025

Conditions
Reflux Esophagitis (RE)
Interventions
DRUG

JP-1366 simulation tablets

qd, last for 4-8 weeks

DRUG

Esomeprazole Magnesium (Nexium) simulation tablets

qd, last for 4-8 weeks

Trial Locations (1)

100050

RECRUITING

Beijing Friendship Hospital, Capital Medical Universtiy, Beijing

Sponsors
All Listed Sponsors
lead

Livzon Pharmaceutical Group Inc.

INDUSTRY